Evidence map›Paper›PMID 41933732›Full record

ArticleThe Journal of biological chemistry2026

Biosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction.

Zabih Mir Hassani, Frédérique Goulet, Duc Tai Nguyen, Anne-Marie Landry-Voyer, Lauren Kwiatek, Shany Gaudet, Pierre-Luc Boudreault, Taha Azad, François Bachand

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zabih Mir HassaniDepartment of Biochemistry & Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke Cancer Research Institute, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Frédérique GouletDepartment of Biochemistry & Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke Cancer Research Institute, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Duc Tai NguyenDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke (IPS), Université de Sherbrooke, Sherbrooke, Québec, Canada.
Anne-Marie Landry-VoyerDepartment of Biochemistry & Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke Cancer Research Institute, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Lauren KwiatekDepartment of Biochemistry & Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke Cancer Research Institute, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Shany GaudetDepartment of Biochemistry & Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke Cancer Research Institute, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Pierre-Luc BoudreaultDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke (IPS), Université de Sherbrooke, Sherbrooke, Québec, Canada.
Taha AzadDepartment of Microbiology and Infectiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke Cancer Research Institute, Université de Sherbrooke, Sherbrooke, Québec, Canada.
François BachandDepartment of Biochemistry & Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke Cancer Research Institute, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: f.bachand@usherbrooke.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death 2 (PDCD2) is an evolutionarily conserved protein essential for cell viability from yeast to humans. PDCD2 functions as a dedicated chaperone to the 40S ribosomal protein uS5, and loss of PDCD2 function impairs ribosome biogenesis. As cancer cells require a substantial supply of ribosomes to maintain elevated levels of protein synthesis, targeting the protein interaction interface between PDCD2 and uS5 is a promising modality to mitigate ribosome biogenesis. In this study, we used affinity purification assays and structural modeling to identify a stretch of 30 amino acids in the N-terminal region of uS5 that is necessary and sufficient for interaction with PDCD2. Our data also identified a conserved FxxGFG motif in uS5 that is important for association with PDCD2 via hydrophobic interactions. Notably, we developed a sensitive complementation-based biosensor that can monitor PDCD2-uS5 interaction in cell extracts and living human cells. Using this biosensor, we identified an 11-amino acid uS5-derived peptide that inhibits the PDCD2-uS5 interaction and impairs cancer cell viability. Such peptides provide a starting point in the development of peptidomimetic inhibitors capable of modulating ribosome biogenesis via disruption of ribosomal protein-dedicated chaperone complexes.

Indexed as

Apoptosis Regulatory ProteinsDrug DiscoveryMolecular ChaperonesPeptidesRibosomal ProteinsCell SurvivalHumansProtein BindingApoptosis Regulatory ProteinsMolecular ChaperonesPeptidesRibosomal Proteinsbioluminescence complementation assaydedicated ribosomal protein chaperonespeptide inhibitorsprogrammed cell death 2 (PDCD2)Protein–protein interaction interfaceribosomal protein uS5 (RPS2)structural modeling

Identifiers

PMID41933732
PMCPMC13127195

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.